Loading, Please Wait...
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it will report second quarter 2019 financial results after the market closes on Thursday, August 8, 2019. Oncternal’s management will host a webcast and conference call at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss the Company’s financial results and provide a comprehensive business update.
A live webcast of the call will be available online via a link from the investor relations page of the Company’s website at www.oncternal.com, and the call will be archived there for at least 30 days.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising, yet untapped biological pathways implicated in cancer generation and progression. Oncternal’s pipeline includes its lead clinical program, cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.
Oncternal Contacts: Investors Richard Vincent 858-434-1113 firstname.lastname@example.org Media Jason Spark 619-849-6005 email@example.com